Study Examining Glofitamab With GemOX in Patients With R/R D

Previously, glofitamab had received an accelerated approval for patients with relapsed or refractory diffuse large B-cell lymphoma who received 2 or more prior lines of systemic therapy.

Related Keywords

Sweden , Swedish , Mabthera Rituxin , Levi Garraway , Krish Patel , Lymphoma Program , Swedish Cancer Institute In Seattle , Global Product Development At Roche , Genentech , Evaluating Glofitamab , Combination With Gemcitabine , Participants With , Refractory Diffuse Largeb Cell , Swedish Cancer Institute , Global Product Development ,